Biology:MCF-7

From HandWiki

MCF-7 is a breast cancer cell line. [1] MCF-7 is the acronym of Michigan Cancer Foundation-7, referring to the institute in Detroit where the cell line was established in 1973 by Herbert Soule and co-workers.[2] The Michigan Cancer Foundation is now known as the Barbara Ann Karmanos Cancer Institute.[3]

MCF-7 and two other breast cancer cell lines, named T-47D and MDA-MB-231, account for more than two-thirds of all abstracts reporting studies on mentioned breast cancer cell lines, as concluded from a Medline-based survey.[4]

Isolation

MCF-7 was isolated in 1970 from a 69-year-old woman. [1] The patient, Frances Mallon died in 1970 due to metastatic breast cancer.[5] Her cells were the source of much of current knowledge about breast cancer.[2][6]

Prior to MCF-7, it was not possible for cancer researchers to obtain a mammary cell line that was capable of living longer than a few months.[7]

Uses

MCF-7 has potential for new drug development, including anti-cancer drug testing, anti-estrogen drug resistance and antiplatelet drug development.[8]

Antiproliferation

Tumor necrosis factor alpha (TNF alpha) inhibits the growth of MCF-7 breast cancer cells. Treatment with anti-estrogens can modulate the secretion of insulin-like growth factor binding proteins. Omega-3 and 6 fatty acids such as EPA, DHA and AA has been reported to inhibit MCF-7 cell line growth and proliferation.[9]

Many studies indicate that the insulin-like growth factor 1 receptor is a crucial therapeutic target for treating cancer in MCF-7 cell lines.[10] One notably effective treatment strategy is silencing this receptor using siRNA packaged in nanoparticles, which significantly suppresses the growth and proliferation of MCF-7 cancer cells.[11]

The results of IC50 determination (Liu et al.) of compounds of Melilotus officinalis (Linn.) Pall. were published during 2018. [12]

Tamoxifen increases FasL and TNF-α. [13]

Characteristics of MCF-7 cells

MCF-7 cells have the following characteristics:[2][6][4][14][15][16]

  • Primary tumor (invasive breast ductal carcinoma)
  • Originate from pleural effusion
  • 17β-estradiol [17] receptors present [8]
  • Proliferative response to estrogens
  • Presence of progesterone receptors
  • Contains 17β-estradiol-binding protein[8]
  • Cannot have ERBB2 gene amplification (with Her2/neu protein overexpression)
  • Tumorigenic in mice but only with estrogen supplementation if engrafted into the subcutaneous fat or mammary fat pad
  • Tumorigenic in mice without estrogen supplementation if engrafted intraductally[18]
  • Luminal epithelial phenotype
  • PIK3CA helical mutations were identified in MCF-7,[19] but with low AKT activation.[20]

This cell line retained several characteristics of differentiated mammary epithelium, including the ability to process estradiol via cytoplasmic estrogen receptors and the capability of forming domes.[21]

References

  1. ↑ 1.0 1.1 Al-hussaniy, Hany; AL-Zobaidy, Mohammed (2024-06-01). "Cytotoxic Effect of YH239-EE and Its Enantiomer on MCF7 Cell Line" (in en). Asian Pacific Journal of Cancer Prevention 25 (6): 2133–2138. doi:10.31557/APJCP.2024.25.6.2133. ISSN 2476-762X. PMID 38918676. PMC 11382848. https://journal.waocp.org/article_91192.html. 
  2. ↑ 2.0 2.1 2.2 Soule, HD; Vazquez J; Long A; Albert S; Brennan M. (1973). "A human cell line from a pleural effusion derived from a breast carcinoma". Journal of the National Cancer Institute 51 (5): 1409–1416. doi:10.1093/jnci/51.5.1409. PMID 4357757. 
  3. ↑ http://www.cancer.gov "NCI Cancer Bulletin for April 29, 2008 - National Cancer Institute". http://www.cancer.gov/ncicancerbulletin/NCI_Cancer_Bulletin_042908/page9.  Retrieved on 2010-04-28
  4. ↑ 4.0 4.1 Lacroix, M; Leclercq G. (2004). "Relevance of breast cancer cell lines as models for breast tumours: an update". Breast Research and Treatment 83 (3): 249–289. doi:10.1023/B:BREA.0000014042.54925.cc. PMID 14758095. 
  5. ↑ Lee, A. V.; Oesterreich, S.; Davidson, N. E. (2015-03-31). "MCF-7 Cells--Changing the Course of Breast Cancer Research and Care for 45 Years" (in en). JNCI Journal of the National Cancer Institute 107 (7). doi:10.1093/jnci/djv073. ISSN 0027-8874. PMID 25828948. https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djv073. 
  6. ↑ 6.0 6.1 Levenson, AS; Jordan VC. (1997). "MCF-7: the first hormone-responsive breast cancer cell line". Cancer Research 57 (15): 3071–3078. PMID 9242427. 
  7. ↑ Glodek, Cass, Ph.D., "A History of the Michigan Cancer Foundation, the Beginnings & Growth of Detroit's Anticancer Movement," 1990, page 68, Michigan Cancer Foundation, Detroit.
  8. ↑ 8.0 8.1 8.2 Comşa, Şerban; Cîmpean, Anca Maria; Raica, Marius (2015-06-01). "The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research" (in en). Anticancer Research 35 (6): 3147–3154. ISSN 0250-7005. PMID 26026074. https://ar.iiarjournals.org/content/35/6/3147. "History - description of ER in the MCF-7 cells in 1973". 
  9. ↑ Mansara, Prakash P.; Deshpande, Rashmi A.; Vaidya, Milind M.; Kaul-Ghanekar, Ruchika (1 September 2015). "Differential Ratios of Omega Fatty Acids (AA/EPA+DHA) Modulate Growth, Lipid Peroxidation and Expression of Tumor Regulatory MARBPs in Breast Cancer Cell Lines MCF7 and MDA-MB-231". PLOS ONE 10 (9). doi:10.1371/journal.pone.0136542. ISSN 1932-6203. PMID 26325577. Bibcode: 2015PLoSO..1036542M. 
  10. ↑ Mennati, Afsaneh; Rostamizadeh, Kobra; Manjili, Hamidreza Kheiri; Fathi, Mojtaba; Danafar, Hossein (2022-03-01). "Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell line". International Journal of Biological Macromolecules 200: 335–349. doi:10.1016/j.ijbiomac.2021.12.197. ISSN 0141-8130. https://linkinghub.elsevier.com/retrieve/pii/S0141813021028439. 
  11. ↑ Mennati, Afsaneh; Rostamizadeh, Kobra; Fathi, Mojtaba (March 2025). "Dual silencing of integrin αvβ3 receptor and insulin-like growth factor 1 receptor using mPEG-PCL/DDAB hybrid nanoparticle loaded siRNA in breast cancer therapy: An in vitro study on MCF-7 cells". International Journal of Biological Macromolecules 294. doi:10.1016/j.ijbiomac.2024.139334. ISSN 1879-0003. PMID 39743068. 
  12. ↑ Yu-Ting Liu (29 January 2018). "Chemical Constituents and Antioxidant, Anti-Inflammatory and Anti-Tumor Activities of Melilotus officinalis (Linn.) Pall". Molecules (China: MDPI) 23 (2): 271. doi:10.3390/molecules23020271. PMID 29382154. 
  13. ↑ Tamilselvan Subramani (25 November 2013). "Vitamin C suppresses cell death in MCF-7 human breast cancer cells induced by tamoxifen: Abstract". J Cell Mol Med 18 (2): 305–313. doi:10.1111/jcmm.12188. PMID 24266867. 
  14. ↑ Ross, DT; Perou CM. (2001). "A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines". Disease Markers 17 (2): 99–109. doi:10.1155/2001/850531. PMID 11673656. 
  15. ↑ Charafe-Jauffret, E; Ginestier C; Monville F; Finetti P; Adelaide J; Cervera N; Fekairi S; Xerri L et al. (2006). "Gene expression profiling of breast cell lines identifies potential new basal markers". Oncogene 25 (15): 2273–2284. doi:10.1038/sj.onc.1209254. PMID 16288205. 
  16. ↑ Lacroix, M; Toillon RA; Leclercq G. (2006). "p53 and breast cancer, an update". Endocrine-Related Cancer (Bioscientifica) 13 (2): 293–325. doi:10.1677/erc.1.01172. PMID 16728565. 
  17. ↑ Samuel C. Brooks; Elizabeth R. Locke; Herbert D. Soule (10 September 1973). "Estrogen Receptor in a Human Cell Line (MCF-7) from Breast Carcinoma". Journal of Biological Chemistry (ASBMB: Elsevier B.V.) 248 (17): 6251–6253. doi:10.1016/S0021-9258(19)43537-0. PMID 4353636. 
  18. ↑ Sflomos, George; Dormoy, Valerian; Metsalu, Tauno; Jeitziner, Rachel; Battista, Laura; Scabia, Valentina; Raffoul, Wassim; Delaloye, Jean-Francois et al. (2016). "A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response". Cancer Cell 29 (3): 407–422. doi:10.1016/j.ccell.2016.02.002. PMID 26947176. 
  19. ↑ Cosmic. "COSMIC: Sample overview for 1289391". http://cancer.sanger.ac.uk/cosmic/sample/overview?id=1289391. 
  20. ↑ Vasudevan, Krishna M.; Barbie, David A.; Davies, Michael A.; Rabinovsky, Rosalia; McNear, Chontelle J.; Kim, Jessica J.; Hennessy, Bryan T.; Tseng, Hsiuyi et al. (2009-07-07). "AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer". Cancer Cell 16 (1): 21–32. doi:10.1016/j.ccr.2009.04.012. ISSN 1878-3686. PMID 19573809. 
  21. ↑ Bullinger, Dino; Neubauer, Hans; Fehm, Tanja; Laufer, Stefan; Gleiter, Christoph H.; Kammerer, Bernd (2007-11-29). "Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling". BMC Biochemistry 8. doi:10.1186/1471-2091-8-25. ISSN 1471-2091. PMID 18047657. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:MCF-7&oldid=4518334"